Digital biomarkers may lead to more robust clinical trials for rare diseases

However, work is still needed to validate their use for rare diseases

Digital biomarkers offer promise for more robust rare-disease clinical trials | Digital biomarkers need validation before use in rare disease trials | Batten Disease News